Source - LSE Regulatory
RNS Number : 8500U
Fusion Antibodies PLC
31 March 2023
 

 

31 March 2023

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Change of registered office

 

Fusion Antibodies plc (AIM: FAB), a contract research organisation providing discovery, design, and optimisation services for therapeutic antibodies to the global healthcare market, announces that it has changed the address of its registered office with immediate effect to:

 

Springbank Industrial Estate

1 Springbank Rd

Dunmurry

Belfast

BT17 0QL

 

Enquiries: 

 

Fusion Antibodies plc

www.fusionantibodies.com

Adrian Kinkaid, Chief Executive Officer

James Fair, Chief Financial Officer

Via Walbrook PR


 

Allenby Capital Limited

Tel: +44 (0)20 3328 5656 

James Reeve/Vivek Bhardwaj (Corporate Finance)

Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 



Walbrook PR

Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com

Anna Dunphy

Mob: +44 (0)7876 741 001

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the discovery and development of antibodies for both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody design, generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry.

 

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. 

 

The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CROFLFVDVEIIVIV
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Fusion Antibodies PLC (FAB)

+0.42p (+12.39%)
delayed 14:05PM